Discovery Leader Of Bb1701 Ipt
CurrentEisai’s co-development program with BlissBio Pharmaceutical. Eisai formed an IPT (international project team) and I was assigned to be a discovery leader of the program.
Please complete the CAPTCHA to continue
A concise factual answer block for searchers comparing this professional profile.
Keiji Furuuchi is listed as Director, Department of Preclinical Development, Pharmacology lead of CLD Domain, DHBL, Eisai Inc.Discovery Leader of FZEC International Project Team Discovery Leader of BB1701 International Project Team at Eisai US, a with 2831 employees, based in Narberth, Pennsylvania, United States. AeroLeads shows a matched LinkedIn profile for Keiji Furuuchi.
Keiji Furuuchi previously worked as Discovery Leader of BB1701 IPT at Eisai Us and Director, Pharmacology lead of CLD (Cell lineage and Differentiation) domain, DHBL. at Eisai Us. Keiji Furuuchi holds Phd, Experimental Pathology, Oncology, Tumor Immunology from Hokkaido University.
This section adds company-level context without repeating Keiji Furuuchi's masked contact details.
Review company-level records connected to Keiji Furuuchi before choosing the right outreach path.
* Translational Research* Preclinical research* Biomarker research* Antidoby Drug Conjugates* Bispecific Antibody* Cancer Vaccine* Tumor Immunology* In vivo tumor studySpecialties: Oncology, Immunology, Antibody Engineering
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Exton, Pennsylvania, United States
Eisai’s co-development program with BlissBio Pharmaceutical. Eisai formed an IPT (international project team) and I was assigned to be a discovery leader of the program.
Exton, Pennsylvania, United States
Eisai Inc restructured new R&D (Oncology and Neurology as Deep-Human Biology Learning) My responsibility as a pharmacology lead of CLD (Cell lineage and Differentiation) domain is to manage late preclinical stage programs for iND submission and to support clinical development by series of preclinical PoC studies of each project.
Exton, Pennsylvania, United States
I was assigned to serve as a discovery lead for FZEC IPT. My responsibility is to conduct any non-clinical studies to support clinical development of FZEC.
Exton, Pennsylvania, United States
A discovery lead in Eisai/BMS joint TR team of FZEC (MORAb-202) Program.
United States
I am currently leading the department of Preclinical Development. My team is in charge of late stage programs for achieving IND submission through BLA. The department also takes responsibilities to demonstrate preclinical POC for middle stages of iND-able programs (i.e therapeutic antibodies, Immunotherapy agent, etc).
United States
Two departments of Pharmacology and Immunotherapy development was merged to form new department, Preclinical development. I was assigned to lead the department. My team took in charge of late stage of programs for achieving IND submission by various preclinical approaches. The department also took responsibilities for middle stages of immunotherapy programs.
United States
The department focus on late stage of programs for the purpose of facilitating IND application. The department also takes responsibilities for middle stages of immunotherapy programs.
United States
The department was placed in newly initiated preclinical development, which focus on late stage of programs for the purpose of facilitating IND application. The department takes responsibilities for those programs and middle stages of immunotherapy agents.
Exton, Pa
The focus of this department will be to advance next generation antibody leads and antibodies to tumor immune targets.
Exton, Pa
Exton, Pa
Other employees you can reach at eisai.com. View company contacts for 2831 employees →
Angelo Wallace
Colleague at Eisai UsChelmsford, England, United Kingdom
View →
RB
Reyalex Barriga
Colleague at Eisai UsNewport Beach, California, United States
View →
YK
Yumi Kondo
Colleague at Eisai UsJapan
View →
EB
Ellen Bereznak
Colleague at Eisai UsBoca Raton, Florida, United States
View →
SG
Sue Gray
Colleague at Eisai UsNashville Metropolitan Area, United States
View →
MC
Mark Cicacci
Colleague at Eisai UsGreater Pittsburgh Region, United States
View →
SJ
Sara Jacob
Colleague at Eisai UsMalvern, Pennsylvania, United States
View →
HD
Heidi Davis-Harris
Colleague at Eisai UsGreater Philadelphia, United States
View →
KA
Kimrua Akifumi
Colleague at Eisai UsJapan
View →
AA
Ashok Althi
Colleague at Eisai UsVisakhapatnam Rural Mandal, India
View →
Quick answers generated from the profile data available on this page.
Keiji Furuuchi works for Eisai US.
Keiji Furuuchi is listed as Director, Department of Preclinical Development, Pharmacology lead of CLD Domain, DHBL, Eisai Inc.Discovery Leader of FZEC International Project Team Discovery Leader of BB1701 International Project Team at Eisai US.
Keiji Furuuchi is based in Narberth, Pennsylvania, United States while working with Eisai US.
Keiji Furuuchi has worked for Eisai Us and Morphotek, Inc..
Keiji Furuuchi's colleagues at Eisai US include Angelo Wallace, Reyalex Barriga, Yumi Kondo, Ellen Bereznak, and Sue Gray.
You can use AeroLeads to view verified contact signals for Keiji Furuuchi at Eisai US, including work email, phone, and LinkedIn data when available.
Keiji Furuuchi holds Phd, Experimental Pathology, Oncology, Tumor Immunology from Hokkaido University.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contactsCheck these profiles if this is not the Keiji Furuuchi you were looking for.